Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dianthus Therapeutics, Inc. - Common Stock (NQ: DNTH ) 27.88 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Dianthus Therapeutics, Inc. - Common Stock Expert Ratings For Dianthus Therapeutics September 26, 2024 Via Benzinga Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September September 04, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Ulta Beauty Reports Downbeat Results, Joins Elastic And Other Big Stocks Moving Lower In Friday's Pre-Market Session August 30, 2024 Via Benzinga Navigating 4 Analyst Ratings For Dianthus Therapeutics August 12, 2024 Via Benzinga DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 09, 2024 DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace What 5 Analyst Ratings Have To Say About Dianthus Therapeutics May 10, 2024 Via Benzinga What 5 Analyst Ratings Have To Say About Dianthus Therapeutics April 18, 2024 Via Benzinga Decoding 4 Analyst Evaluations For Dianthus Therapeutics February 15, 2024 Via Benzinga Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results August 08, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) June 28, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) June 12, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference May 30, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher January 22, 2024 Dianthus Therapeutics shares traded higher by 37% Monday. The company announced a $230 million private placement. Via Benzinga DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results May 09, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference May 08, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting April 11, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 05, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 22, 2024 Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results. Via Benzinga Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday March 22, 2024 U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday. Via Benzinga Topics Stocks Exposures US Equities DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 March 21, 2024 DNTH stock results show that Dianthus Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. Via InvestorPlace Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 07, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) February 26, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 December 14, 2023 Dianthus Therapeutics just reported results for the third quarter of 2023. Via InvestorPlace Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst November 22, 2023 Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the Via Benzinga Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst September 28, 2023 Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 September 28, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.